[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kumud Kalia, Chief Information Officer of Guardant Health (GH), reported a sale of 2,000 shares of the company's common stock on 08/21/2025 at a reported price of $61.755 per share. After this transaction the filing shows 18,500 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact on 08/22/2025 and discloses the officer role and timely reporting of the change in ownership.

Positive

• Timely disclosure of insider sale filed via Form 4 and signed on 08/22/2025
• Clear reporting of transaction details: date, price ($61.755) and quantity (2,000 shares)

Negative

• Officer sale of 2,000 shares reduces beneficial ownership to 18,500 shares

Insights

Financial Analyst

TL;DR: Officer sale of 2,000 shares at $61.755 reduces holdings to 18,500 shares; routine insider disclosure with limited market impact.

The reported sale is a straightforward Section 16 transaction by Guardant Health's CIO. The sale size is disclosed clearly with price and post-transaction holdings. There is no accompanying information about the reason for the sale, any derivative transactions, or planned trading arrangements in this filing. For valuation or market-impact conclusions, additional context such as total outstanding shares, recent insider activity, or company-specific events would be required but is not present in this document.

Corporate Governance Expert

TL;DR: Filing meets disclosure obligations; officer sale documented and signed by attorney-in-fact, with no governance red flags in this form alone.

The Form 4 provides required disclosure of an insider disposition and identifies the reporting person as an officer. The signature by attorney-in-fact indicates the filing was executed on the reporter's behalf. The filing does not show any exceptions, amendments, or derivative activity. On its face, this is a routine compliance filing rather than a governance concern; however, governance implications would need evaluation alongside other insider transactions and context not contained here.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalia Kumud

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Information Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S		2,000	D	$61.755	18,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Kumud Kalia	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Guardant Health (GH) insider Kumud Kalia report?

The Form 4 reports a sale of 2,000 shares of Guardant Health common stock on 08/21/2025 at a price of $61.755 per share.

How many Guardant Health shares does the reporting person own after the transaction?

Following the reported sale, the filing shows the reporting person beneficially owns 18,500 shares.

What is Kumud Kalia's role at Guardant Health as stated in the filing?

The filing identifies Kumud Kalia as the company's Chief Information Officer and an officer-level reporting person.

When was the Form 4 signed and filed?

The Form 4 was signed by an attorney-in-fact on 08/22/2025; the underlying transaction date is 08/21/2025.

Does the filing show any derivative transactions or a 10b5-1 plan?

No. The Form 4 contains only a non-derivative sale of common stock and does not disclose any derivative transactions or indicate a 10b5-1 plan.